Company Filing History:
14 out of 36 
2 out of 440 
1 out of 16 Years Active: 2015-2025
Title: Rachida Siham Bel Aiba: Innovator in Cancer Therapeutics
Introduction
Rachida Siham Bel Aiba is a prolific inventor based in Munich, Germany, with an impressive portfolio of 18 patents focusing on innovative therapeutic approaches in the field of oncology. Her work has significantly contributed to the development of novel proteins and polypeptides that hold promise for the treatment and prevention of various human diseases, including cancer.
Latest Patents
Among her latest patents is a remarkable invention concerning "Proteins Specific for CD137." This disclosure reveals human lipocalin muteins that bind CD137 and have potential applications in pharmaceuticals as anti-cancer agents and immune modulators. Additionally, the invention discusses methods for creating these lipocalin muteins, along with nucleic acid molecules encoding them and compositions containing these muteins for therapeutic and diagnostic uses.
Another notable patent is the "Anti-cancer Fusion Polypeptide Capable of Binding Both CD137 and Glypican-3 (GPC3)." This fusion polypeptide can effectively direct CD137 clustering and activation toward GPC3-positive tumor cells, presenting a promising avenue for anti-cancer therapies. The disclosure also explores methods for its production and therapeutic applications, showcasing the innovative nature of Bel Aiba's work.
Career Highlights
Rachida has built her career in esteemed organizations, including Pieris Pharmaceuticals GmbH and Daiichi Sankyo Company, Limited. Through her dedication and expertise, she has established herself as a key figure in the development of advanced therapeutic solutions in the life sciences sector.
Collaborations
Throughout her career, Rachida has collaborated with talented professionals like Christine Rothe and Andrea Allersdorfer. These collaborations reflect her commitment to fostering innovative research and her ability to work effectively within multidisciplinary teams, aiming to advance cancer treatment methodologies.
Conclusion
Rachida Siham Bel Aiba's pioneering contributions to the field of oncology, exemplified by her numerous patents and collaborative efforts, underscore her status as a significant inventor in the biopharmaceutical industry. Her innovative approaches to developing CD137-targeting therapies highlight the potential of her inventions to transform cancer treatment and improve patient outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.